These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 20061360)

  • 1. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study.
    Miller ME; Bonds DE; Gerstein HC; Seaquist ER; Bergenstal RM; Calles-Escandon J; Childress RD; Craven TE; Cuddihy RM; Dailey G; Feinglos MN; Ismail-Beigi F; Largay JF; O'Connor PJ; Paul T; Savage PJ; Schubart UK; Sood A; Genuth S;
    BMJ; 2010 Jan; 340():b5444. PubMed ID: 20061360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.
    Bonds DE; Miller ME; Bergenstal RM; Buse JB; Byington RP; Cutler JA; Dudl RJ; Ismail-Beigi F; Kimel AR; Hoogwerf B; Horowitz KR; Savage PJ; Seaquist ER; Simmons DL; Sivitz WI; Speril-Hillen JM; Sweeney ME
    BMJ; 2010 Jan; 340():b4909. PubMed ID: 20061358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.
    Ismail-Beigi F; Craven T; Banerji MA; Basile J; Calles J; Cohen RM; Cuddihy R; Cushman WC; Genuth S; Grimm RH; Hamilton BP; Hoogwerf B; Karl D; Katz L; Krikorian A; O'Connor P; Pop-Busui R; Schubart U; Simmons D; Taylor H; Thomas A; Weiss D; Hramiak I;
    Lancet; 2010 Aug; 376(9739):419-30. PubMed ID: 20594588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial.
    ; Mellbin LG; Rydén L; Riddle MC; Probstfield J; Rosenstock J; Díaz R; Yusuf S; Gerstein HC
    Eur Heart J; 2013 Oct; 34(40):3137-44. PubMed ID: 23999452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy.
    Launer LJ; Miller ME; Williamson JD; Lazar RM; Gerstein HC; Murray AM; Sullivan M; Horowitz KR; Ding J; Marcovina S; Lovato LC; Lovato J; Margolis KL; O'Connor P; Lipkin EW; Hirsch J; Coker L; Maldjian J; Sunshine JL; Truwit C; Davatzikos C; Bryan RN;
    Lancet Neurol; 2011 Nov; 10(11):969-77. PubMed ID: 21958949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers associated with severe hypoglycaemia and death in ACCORD.
    Chow LS; Chen H; Miller ME; Marcovina SM; Seaquist ER
    Diabet Med; 2016 Aug; 33(8):1076-83. PubMed ID: 26261902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.
    Lund SS; Tarnow L; Frandsen M; Nielsen BB; Hansen BV; Pedersen O; Parving HH; Vaag AA
    BMJ; 2009 Nov; 339():b4324. PubMed ID: 19900993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial.
    Hempe JM; Liu S; Myers L; McCarter RJ; Buse JB; Fonseca V
    Diabetes Care; 2015 Jun; 38(6):1067-74. PubMed ID: 25887355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial.
    Davies M; Lavalle-González F; Storms F; Gomis R;
    Diabetes Obes Metab; 2008 May; 10(5):387-99. PubMed ID: 18355327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
    Heller SR; Bergenstal RM; White WB; Kupfer S; Bakris GL; Cushman WC; Mehta CR; Nissen SE; Wilson CA; Zannad F; Liu Y; Gourlie NM; Cannon CP;
    Diabetes Obes Metab; 2017 May; 19(5):664-671. PubMed ID: 28058763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
    van der Leeuw J; Visseren FL; Woodward M; van der Graaf Y; Grobbee DE; Harrap S; Heller S; Mancia G; Marre M; Poulter N; Zoungas S; Chalmers J
    Diabetologia; 2016 Dec; 59(12):2603-2612. PubMed ID: 27586250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive glucose control and cardiovascular outcomes in type 2 diabetes.
    Macisaac RJ; Jerums G
    Heart Lung Circ; 2011 Oct; 20(10):647-54. PubMed ID: 20807681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with failure to achieve a glycated haemoglobin target of <8.0% in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
    Drake TC; Hsu FC; Hire D; Chen SH; Cohen RM; McDuffie R; Nylen E; O'Connor P; Rehman S; Seaquist ER
    Diabetes Obes Metab; 2016 Jan; 18(1):92-5. PubMed ID: 26435375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study.
    Heller SR; Geybels MS; Iqbal A; Liu L; Wagner L; Chow E
    Diabetologia; 2022 Jan; 65(1):55-64. PubMed ID: 34704120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study.
    Wolnik B; Wiza D; Szczepanik T; Syta A; Klupa T
    J Diabetes Res; 2020; 2020():8751348. PubMed ID: 32337298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
    Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
    Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low risk of severe hypoglycaemia in patients with type 2 diabetes mellitus starting insulin therapy with premixed insulin analogues BID in outpatient settings.
    Pīrāgs V; El Damassy H; Dąbrowski M; Gönen MS; Račická E; Martinka E; Giaconia J; Stefanski A;
    Int J Clin Pract; 2012 Nov; 66(11):1033-41. PubMed ID: 23067027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
    Fulcher GR; Gilbert RE; Yue DK
    Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers related to severe hypoglycaemia and lack of good glycaemic control in ACCORD.
    Chow LS; Chen H; Miller ME; Marcovina SM; Seaquist ER
    Diabetologia; 2015 Jun; 58(6):1160-6. PubMed ID: 25652389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
    Garber AJ; King AB; Del Prato S; Sreenan S; Balci MK; Muñoz-Torres M; Rosenstock J; Endahl LA; Francisco AM; Hollander P;
    Lancet; 2012 Apr; 379(9825):1498-507. PubMed ID: 22521072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.